Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Innovent Reports Positive Data from Phase III Trial of PCSK-9 Cholesterol Drug

publication date: Apr 5, 2022

Suzhou Innovent Biologics reported its anti-PCSK-9 mAb successfully lowered cholesterol levels in a China Phase III trial that enrolled people with hypercholesterolemia. Innovent said IBI306 was similar in efficacy to western PCSK-9 therapies but with less-frequent dosings. After 12 weeks, IBI306 reduced LDL-C levels by up to 62% on a 450 mg dose administered every four weeks. Enrolled patients had non-familial hypercholesterolemia (hypercholesterolemia with cardiovascular risk) (HeFH). Innovent plans to file an NDA in China for the drug this year. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital